x

This website uses cookies to improve your experience. Continue if you are OK with this or read more in our privacy policy. 




Teva faces $2 billion damages for selling generic Protonix

18-02-2013

Israeli company Teva Pharmaceuticals could be forced to pay more than $2 billion in damages for selling a generic version of Nycomed and Pfizer’s heartburn reliever Protonix before the drug’s patent exclusivity expired in the US.


Teva, Pfizer, Nycomed, Protonix, generic, damages

WIPR

Payment types accepted